Northwest Biotherapeutics, Inc. · OTC:NWBO
Northwest Biotherapeutics — Brain Tumor Biotech Summit 2013
24 slides from Northwest Biotherapeutics's conference presentation, Jun 7, 2013
Slide 1: Dendritic Cell-Based Immunotherapies for Brain Tumors
Dendritic Cell-Based Immunotherapies for Brain Tumors Brain Tumor Biotech Summit June 7, 2013
Slide 2: Disclaimer
Disclaimer Certain statements made in this presentation are “forward-looking statements” of NWBT as defined by the Securities and Exchange Commission (“SEC”). All statements, other than statements of historical fact, included in this presentation that address activities, events or developments that
Slide 3: Company and Portfolio Overview
Company and Portfolio Overview • NWBio is a US-based biotechnology company with a European subsidiary located in Germany • NWBio’s portfolio comprises living cell, active immunotherapy products for the treatment of cancer • The company’s technology platform is based around autologous dendritic cells
Slide 4: DCVax Clinical Trial Options
DCVax Clinical Trial Options Cancer Diagnosis Resectable Not Resectable DCVax-L DCVax-Direct Protocol 020221 Protocol 050012 •For new GBM •For solid tissue tumors •For solid tissue tumors with brain metatases 4
Slide 5: DCVax-L Clinical Trials in Patients with Glioblastoma multiforme
DCVax®-L Clinical Trials In Patients with Glioblastoma multiforme
Slide 6: DCVax-L Clinical Development
DCVax-L Clinical Development First Phase I/II trial in GBM brain cancer Second Phase 2000-021 I/II trial in GBM Non- Blinded, randomized, controlled brain cancer blinded 2003-061 , rando m-ized Phase II Trial Phase 2007 I/II trial in ovarian cancer 2000 01 02 03 04 05 06 07 08 09 10 11 12 FDA approv
Slide 7: Phase III Trial Design
Phase III Trial Design • Multi-center, double blind, placebo controlled with cross-over • ~300 patients, randomized 2:1 (treatment:placebo) • DCVax-L adjuvant to standard of care (surgery, radiation, Temodar®) • DCVax-L immunizations interspersed with adjuvant Temodar® • 10 immunizations (induction,
Slide 8: International Expansion of Phase III trial
International Expansion of Phase III trial • The Phase III clinical trial is approved by MHRA (UK) – German authorization is pending • King’s College Hospital, London, is now recruiting patients • Additional site preparations are underway in the UK and Germany • Fraunhofer IZI has obtained manufactu
Slide 9: DCVax-L Phase III Trial – Projections
DCVax-L Phase III Trial – Projections • Recruitment to continue through Q2 of 2014 • Interim analyses (DSMB) late 2013 and early 2014 • Final analysis Q3 of 2014 9
Slide 10: DCVax-Direct
ih _\ NORTHWEST |. BIOTHERAPEUTICS DCVax-Direct® 10
Slide 11: DCVax-Direct
DCVax-Direct • DCVax-Direct: autologous, activated dendritic cells (DC) for intra-tumoral injection • Potential indications: all non-resectable (inoperable) solid tumors, such as: o Liver cancer o Liver metastases of colon cancer o Head and neck cancer o Esophageal cancer o Prostate cancer o Other c
Slide 12: Manufacturing DCVax-Direct
Manufacturing DCVax-Direct 12
Slide 13: Tangential Flow Filtration (TFF)
Tangential Flow Filtration (TFF) Filtration: To WASTE Inlet Filter vent Collection Unit Recirculation Product
Slide 14: The “Activated DC” Concept
The “Activated DC” Concept • The manufacturing system produces true immature DC • Activation of these DC starts with adding maturation agents to the bag • Full maturation takes 48 – 72 hours • Harvesting the DC prior to full maturation results in Activated DC • Activated DC: – Can still take up and
Slide 15: Immature DC granularity and size
Immature DC “granularity” Dendritic cells lymphocytes “size” 15
Slide 16: Cytokine production DCVax-Direct
Cytokine production DCVax-Direct 16
Slide 17: DCVax-Direct Clinical Trials (1)
DCVax-Direct Clinical Trials (1) • IND cleared by FDA for all solid tumor cancers, including metastatic to the brain if there is still an injectable lesion below the neck • Phase I/II combined trial -- Part I: dose-finding -- Part II: efficacy • First site scheduled to open for recruitment soon • Th
Slide 18: DCVax-Direct: Striking Pre-Clinical Results
DCVax®-Direct: Striking Pre-Clinical Results Tumor clearance on same side of body after direct injection in animal studies 250 250 Tum or Siz e (m m 2) Tum or S ize (m m 2) 200 200 + chemo 150 150 partially only 100 100 activated 50 50 DCs 0 0 0 7 14 21 28 35 42 0 7 14 21 28 35 42 Day Post Tumor Ino
Slide 19: DCVax-Direct: Striking Pre-Clinical Results
DCVax®-Direct: Striking Pre-Clinical Results Tumor clearance on opposite side of body after direct injection in animal studies 250 250 200 + Tumor Size (mm2) 200 chemo 150 partially Tumor Size (mm2) only 150 100 activated 100 DCs 50 50 0 0 7 14 21 28 35 42 0 0 7 14 21 28 35 42 Day Day 250 250 200 +
Slide 20: Intra-tumoral Injection: Observations
Intra-tumoral Injection: Observations • Intra-tumoral injection is best preceded by some form of other cytoreductive therapy • Intra-tumoral injection of activated DC results in dramatic enhancement in efficacy: Eradication of tumors injected Eradication of contralateral non-injected tumors Obse
Slide 21: Acknowledgments
Acknowledgments NORTHWEST BIOTHERAPEUTICS DCVAX-L PHASE III INVESTIGATORS Linda Powers AND SITE PERSONNEL Les Goldman Anthony Maida COGNATE BIOSERVICES Alton Boynton Meghan Swardstrom Julie McEarchern UCLA Linda Liau Robert Prins 21
Slide 22: Appendix
it |). NORTHWEST | BIOTHERAPEUTICS Appendix 22
Slide 23: Newly Diagnosed GBM: Progression Free Survival
Newly Diagnosed GBM: Progression Free Survival 1.0 0.9 “P value” = 0.00001 (i.e., 1 in 100,000 probability that 0.8 these trial results were random) Proportion not progressed 0.7 0.6 Patients 0.5 treated with 0.4 DCVax®-L 0.3 Matched patients 0.2 treated at same hospital, with Standard of Care 0.1 8
Slide 24: Newly Diagnosed GBM: Overall Survival
Newly Diagnosed GBM: Overall Survival 1.0 P value = 0.0003 0.9 (i.e., 3 in 10,000 probability that these trial results were random) 0.8 Proportion surviving 0.7 0.6 0.5 Patients 0.4 treated with DCVax®-L 0.3 0.2 Matched patients 0.1 treated at same hospital, 17 36.4 with Standard of Care 0.0 0 20 40
Northwest Biotherapeutics — Brain Tumor Biotech Summit 2013 on 6ix